Phospho-CHK1 (Ser317) Polyclonal Antibody, Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PIPA5117349-Each-of-1 | In Stock | ₹ 46,502.50 |
PIPA5117349 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 46,502.50
GST (18%): ₹ 8,370.45
Total Price: ₹ 54,872.95
Antigen
Phospho-CHK1 (Ser317)
Classification
Polyclonal
Conjugate
Unconjugated
Gene
Chek1
Gene Alias
C85740; Cell cycle checkpoint kinase; checkpoint kinase 1; checkpoint kinase 1 homolog; checkpoint kinase-1; Checkpoint, S. pombe, homolog of, 1; CHEK1; CHK1; CHK1 checkpoint homolog; Chk1-S; homolog of Chk1-S; HRD1 Protein; rad27; rad27 homolog; serine/threonine protein kinase CHK1; serine/threonine-protein kinase Chk1; Synoviolin; YBR1742; YBR274W
Host Species
Rabbit
Purification Method
Antigen affinity chromatography
Regulatory Status
RUO
Gene ID (Entrez)
1111
Content And Storage
-20° C, Avoid Freeze/Thaw Cycles
Form
Liquid
Applications
Immunocytochemistry, Western Blot
Concentration
2.2 mg/mL
Formulation
PBS with 1% BSA, 20% glycerol and 0.025% ProClin 300; pH 7
Gene Accession No.
O14757
Gene Symbols
Chek1
Immunogen
Carrier-protein conjugated synthetic peptide corresponding to residues around human Chk1 (phospho Ser317). The exact sequence is proprietary.
Quantity
100 μL
Primary or Secondary
Primary
Target Species
Human
Product Type
Antibody
Isotype
IgG
Related Products
Description
- Centrifuge briefly prior to opening
- CHEK1 (CHK1) is a serine/threonine protein kinase involved in preventing replication when DNA integrity is compromised
- CHK1 is a key mediator in the DNA damage-induced checkpoint network
- CHK1 is an evolutionarily conserved protein kinase that functions to ensure genomic integrity upon genotoxic stress
- When the G2 or S checkpoint is abrogated by the inhibition of CHK1, p53-deficient cancer cells undergo mitotic catastrophe and eventually apoptosis, whereas normal cells are still arrested in the G1 phase
- Thus, CHK1 inhibitors can preferentially potentiate the efficacy of DNA damaging agents in cancer cells, and Chk1 is an attractive therapeutic target for cancer treatment, especially since approximately 50% of all human cancers are p53-deficient.